Business Context and Reporting Period
This Form 8-K Current Report is filed by Synta Pharmaceuticals Corp. (not Madrigal Pharmaceuticals, as indicated in the metadata request) on November 24, 2014, with the earliest event reported on that date. The filing primarily addresses Item 5.02 regarding the appointment of new executive officers and the departure of the Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and employment terms.
Material Changes
The Company announced significant changes to its executive leadership effective December 8, 2014:
- Appointment of Chen Schor: Named Executive Vice President and Chief Operating Officer.
- Appointment of Marc R. Schneebaum: Named Senior Vice President and Chief Financial Officer.
- Departure of Keith S. Ehrlich: Stepping down as Chief Financial Officer, effective December 8, 2014, with a transition period to follow.
Compensation, Guidance, and Risks
The filing details the compensatory arrangements for the new executives, which include base salaries, bonuses, equity grants, and severance protections.
Chen Schor (EVP & COO)
- Base Salary: $425,000 annually.
- Target Bonus: 50% of base salary.
- Sign-on Bonus: $50,000 (subject to clawback provisions).
- Equity Grants: Options for 450,000 shares and 150,000 shares of restricted stock (granted outside the 2006 Stock Plan).
- Severance: 12 months' salary and benefits for termination without Cause/Good Reason; 18 months' salary, full bonus, and full equity acceleration upon Change of Control.
Marc R. Schneebaum (SVP & CFO)
- Base Salary: $325,000 annually.
- Target Bonus: 40% of base salary.
- Relocation: Reimbursement for relocation and up to $20,000 for temporary living/travel expenses.
- Equity Grants: Options for 225,000 shares and 75,000 shares of restricted stock (granted outside the 2006 Stock Plan).
- Severance: 6 months' salary and benefits for termination without Cause/Good Reason; 12 months' salary, full bonus, and full equity acceleration upon Change of Control.
Risks and Contingencies: Both executives are subject to non-competition and non-solicitation agreements for 12 months post-employment. The filing notes no related party transactions or family relationships requiring disclosure.
Investor Verification Checklist
- Verify the exact commencement date of December 8, 2014, for the new officers.
- Confirm the terms of the "Schor Agreement" and "Schneebaum Agreement" filed as Exhibits 10.1 and 10.3.
- Review the specific vesting schedules for the equity grants (25% cliff vesting followed by quarterly vesting for options; 50/50 split over years 2 and 3 for restricted stock).
- Assess the impact of the CFO transition on the Company's financial reporting and strategic direction.
- Note that the equity grants were made outside the existing 2006 Stock Plan as an inducement under NASDAQ rules.